A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Immunity logo

Kolev M, West EE, et al. Immunity. 2020 Mar 17. Diapedesis-Induced Integrin Signaling via LFA-1 Facilitates Tissue Immunity by Inducing Intrinsic Complement C3 Expression in Immune Cells.

genOway has generated C3-reporter mice (C3IRES‑tdTomato C57BL/6 mice) for a group of researchers, led by Claudia Kemper, who recently published their findings in Immunity.

C3 is a protein that plays a critical role in activating the complement system: several studies have indeed shown that increased C3 levels result in autoimmunity, while decreased C3 levels give rise to higher susceptibility to bacterial and viral infections. In this study, the authors demonstrated that these defects can be corrected by restoring intracellular C3 via adenovirus- or electroporation-mediated in vivo delivery.

The C3-reporter mice are therefore invaluable tools to monitor the intracellular expression of C3 in vivo, and distinguish inflamed versus uninflamed tissues.

Commented by Alessia Armezzani, PhD (Apr 2020)

 

For more information on genOway’s customized mouse models, please follow the link:

https://www.genoway.com/services/customized-mouse/overview.htm

 

Nature Neuroscience – March 2020 – Cxcr4CreER(T2)-IRES-eGFP Knockin mouse model as a universal tool to study...

nature neuroscience

The Cxcr4CreER(T2)-IRES-eGFP Knockin mouse model as a universal tool to study functions of hematopoietic stem cell (HSC)-derived cells

Werner Y, et al. Cxcr4 distinguishes HSC‑derived monocytes from microglia and reveals monocyte immune responses to experimental stroke. Nat Neurosci. 2020

 

Commented by Alessia Armezzani, PhD (Mar 2020)

The Cxcr4 Knockin mouse model was designed and generated by genOway for a group of researchers, led by Prof. Ralf Stumm, who recently published their work in Nature Neuroscience.

By taking advantage of the CreER(T2)-IRES-eGFP design, the authors could distinguish HSC‑derived monocytes from tissue-resident microglia and macrophages, and demonstrate that Cxcr4 promotes initial monocyte infiltration and subsequent territorial restriction of monocyte-derived macrophages to infarct tissue.

This model is a powerful tool to:

  • Trace the lineage of HSC-derived cells such as monocytes and microglia, due to eGFP expression under the control of the Cxcr4 promoter
  • Track monocyte fate and function in injured brain tissues (e.g., experimental stroke), due to the inducible expression of Cre upon tamoxifen induction

 

Figure: Immunofluorescences for GFP, Iba1 and Tmem119 reveals the presence of Cxcr4+ cells after stroke induction in coronal brain sections. Interestingly, Cxcr4 is expressed in infiltrating monocytes, but not in reactive microglia.

image 01

Alessia is scientific communication manager at genOway

 

For more information on genOway’s customized mouse models:

https://www.genoway.com/services/customized-mouse/overview.htm

Science – Feb 2020 – VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.

science.mag

Humanized Immune Checkpoint VISTA mouse model contributes to research published in Science

ElTanbouly MA, Zhao Y, et al. Science. 2020
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance. 

 

Commented by Alessia Armezzani, PhD (Feb 2020)

A humanized VISTA mouse developed by genOway has proved to be an excellent tool to unveil a new role for this immune checkpoint inhibitor, already known to play a key role in suppressing T cell activation.

In this study, freshly published in Science, a team of researchers at the Geisel School of Medicine at Dartmouth and ImmuNext performed in vivo analyses, demonstrating that VISTA is critical in maintaining T cell self-tolerance. This was elegantly shown by targeting VISTA with agonist and antagonist antibodies, whose specificity was assessed in the humanized VISTA mouse model as well as in other human and murine samples.

 

 

Alessia is scientific communication manager at genOway

 

For more information on genOway’s humanized immune checkpoint catalog, please follow the link:

Cell – Jan 2020 – A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout...

cell

Matheis F, Muller PA, Graves CL, Gabanyi I, Kerner ZJ, Costa-Borges D, Ahrends T, Rosenstiel P, Mucida D.
Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss.
Cell. 2020 Jan.

 

Commentary by Alessia Armezzani, PhD (Jan 2020)

A recent study, freshly published in Cell by a group of researchers at Rockefeller University, demonstrates that enteric infections cause rapid neuronal loss via the two non-canonical inflammasomes Nlrp6 and Casp11. This was elegantly demonstrated by infecting conditional Knockout mice with an attenuated strain of Salmonella enterica and, subsequently, quantifying the numbers of enteric neurons.

 

 

In addition, researchers found that resident macrophages rapidly respond to enteric pathogens by activating the β2-adrenergic receptor (β2-AR) signaling that, in turn, triggers the synthesis of neuroprotective polyamines, thereby limiting neuronal loss. These findings suggest an extremely sophisticated interplay between enteric neurons and macrophages similar to what has been already described for the central nervous system.

Alessia is scientific communication manager at genOway

Nature – Oct 2019 – VISTA is an acidic pH-selective ligand for PSGL-1.

 nature

Johnston RJ, Su LJ, Pinckney J, Critton D, Boyer E, Krishnakumar A, Corbett M, Rankin AL, Dibella R, Campbell L, Martin GH, Lemar H, Cayton T, Huang RY, Deng X, Nayeem A, Chen H, Ergel B, Rizzo JM, Yamniuk AP, Dutta S, Ngo J, Shorts AO, Ramakrishnan R, Kozhich A, Holloway J, Fang H, Wang YK, Yang Z, Thiam K, Rakestraw G, Rajpal A, Sheppard P, Quigley M, Bahjat KS, Korman AJ.
VISTA is an acidic pH-selective ligand for PSGL-1.
Nature. 2019 Oct.

 

Commentary by Alessia Armezzani, PhD (Oct 2019)

Immune checkpoint inhibitors play a critical role in cancer suppression.(1,2) For this reason, antibodies targeting immune checkpoint inhibitors such as CTLA-4 and PD-1 have become standard of care in an increasing number of solid tumors, including metastatic melanomas, non-small-cell lung carcinomas and liver cancer.(3) These immunotherapies offer patients a durable remission from diseases whose outcomes were previously invariably terminal; over time, however, some tumors become resistant to such molecules due to innate and acquired resistance. These limitations have pushed scientists to understand the biological mechanisms responsible for the development of such resistances, and establish new therapeutic strategies.(4)

VISTA is an immune checkpoint inhibitor that has been identified as a potential mediator of resistance to anti-CTLA-4 and anti-PD-1 immunotherapies.(5,6) However, to date, it has not been frequently used for therapeutic intervention due to a lack of understanding of its mechanism of action in immune responses.

Image VISTA

Along these lines, a study conducted by a group of researchers at Bristol-Myers Squibb, freshly published in Nature, shed some light on VISTA and its interaction with PSGL-1.(7) In particular, Johnston and colleagues found that VISTA binds and suppresses T cells at acidic pH such as that typically measured in tumor microenvironments. Pharmacokinetic experiments conducted on our humanized VISTA mice treated with VISTA-blocking antibodies showed indeed that acidic pH-selective antibodies accumulate preferentially within tumors and exhibit longer serum mean resistance time than non-pH-selective antibodies. Moreover, the authors demonstrated that tumor growth in human VISTA Knockin mice bearing mouse colorectal carcinoma MC38 cells is significantly reduced in animals treated with combination therapy (anti-VISTA and anti-PD-1) compared to those that received monotherapy (anti-PD-1).

Alessia is scientific communication manager at genOway

 


References:

  1. Paluch, Christopher, et al. "Immune checkpoints as therapeutic targets in autoimmunity." Front Immunol. 2018 Oct 8
  2. Armezzani, A. "Immune checkpoint inhibitors: A strategy to tackle cancer?" genOway, 2019 Jul
  3. Darvin, Pramod, et al. "Immune checkpoint inhibitors: recent progress and potential biomarkers." Exp Mol Med. 2018 Dec 13
  4. Wang, Jinghua, et al. "VSIG‐3 as a ligand of VISTA inhibits human T‐cell function." Immunology. 2019 Jan
  5. Kakavand, Hojabr, et al. "Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients." Mod Pathol. 2017 Dec
  6. Nowak, Elizabeth C., et al. "Immunoregulatory functions of VISTA." Immunol Rev. 2017 Mar
  7. Johnston, Robert J., et al. "VISTA is an acidic pH-selective ligand for PSGL-1." Nature. 2019 Oct